RxDoctor Payments Data

Ted Coy, MD

Internal Medicine · Southfield, MINPI 1740273069

Payments from drug & device makers

$1,123in general payments, 2019–2025

Across 68 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$349
  • Novartis$125
  • GSK$93
  • Amgen$85
  • Pfizer$76
  • Novo Nordisk$62
  • plus $332 from 8 others

What the payments were for

  • Food & beverage$1,09497%
  • Education$293%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,123 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$60,886
Medicare patients
186
Services billed
917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban293$313,030
JardianceEmpagliflozin215$227,846
Trelegy ElliptaFluticasone/Umeclidin/Vilanter110$105,981
XareltoRivaroxaban48$53,961
TrulicityDulaglutide31$53,297
FarxigaDapagliflozin Propanediol65$52,505
OzempicSemaglutide26$46,283
Teriparatide11$41,973
JanuviaSitagliptin Phosphate32$31,429
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog24$28,292
Tresiba Flextouch U-200Insulin Degludec24$23,456
Spiriva RespimatTiotropium Bromide24$20,621
Combivent RespimatIpratropium/Albuterol Sulfate32$20,436
MounjaroTirzepatide21$19,440
MyrbetriqMirabegron27$17,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$313,030293 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$44$282,876282 claims
GSKTrelegy Ellipta$93$105,981110 claims
Lilly USA, LLCTrulicity, Mounjaro$50$72,73752 claims
Johnson & JohnsonXarelto$46$53,96148 claims
AstraZenecaFarxiga$349$52,50565 claims
Novo NordiskOzempic$62$46,28326 claims
MerckJanuvia$44$31,42932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →